Brokers Offer Predictions for Disc Medicine Q1 Earnings

Key Points

• Disc Medicine reported a quarterly loss of $1.53 per share, beating analysts’ consensus estimate of a $1.63 loss by $0.10.
• HC Wainwright forecasts a $1.53-per-share loss for Q1 2027 and maintains a Buy rating with a $127 price target. Analysts’ consensus rating is “Moderate Buy,” with an average target of $123.40.
• Institutional investors own 83.70% of the shares, while company insiders sold 168,046 shares worth about $13.2 million over the past three months.

Disc Medicine, Inc. (NASDAQ:IRON - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2027 EPS estimates for shares of Disc Medicine in a research report issued on Friday, November 6th. HC Wainwright analyst D. Tsao anticipates that the company will post earnings of ($1.53) per share for the quarter. HC Wainwright has a "Buy" rating and a $127.00 price objective on the stock. The consensus estimate for Disc Medicine's current full-year earnings is ($6.54) per share.

Disc Medicine (NASDAQ:IRON - Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The company reported ($1.53) EPS for the quarter, beating the consensus estimate of ($1.63) by $0.10.

IRON has been the subject of several other research reports. Jefferies Financial Group restated a "buy" rating and set a $149.00 price target on shares of Disc Medicine in a report on Wednesday, October 21st. Cantor Fitzgerald lifted their price objective on Disc Medicine from $125.00 to $170.00 and gave the stock an "overweight" rating in a research note on Monday, October 19th. Wedbush upped their price objective on Disc Medicine from $100.00 to $110.00 and gave the stock an "outperform" rating in a report on Monday, October 19th. BMO Capital Markets increased their target price on Disc Medicine from $100.00 to $120.00 and gave the company an "outperform" rating in a research report on Monday, October 19th. Finally, Morgan Stanley raised their target price on shares of Disc Medicine from $90.00 to $92.00 and gave the company an "overweight" rating in a report on Tuesday, October 20th. Eleven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $123.40.

Disc Medicine Price Performance

NASDAQ:IRON opened at $78.91 on Monday. The company has a current ratio of 24.14, a quick ratio of 24.14 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $3.03 billion, a P/E ratio of -12.45 and a beta of 0.96. Disc Medicine has a 12 month low of $40.00 and a 12 month high of $99.50. The business's 50-day moving average is $71.21 and its 200 day moving average is $70.93.

Institutional Investors Weigh In On Disc Medicine

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new stake in shares of Disc Medicine in the 2nd quarter valued at approximately $180,502,000. Wellington Management Group LLP increased its position in shares of Disc Medicine by 0.3% during the 2nd quarter. Wellington Management Group LLP now owns 1,741,351 shares of the company's stock valued at $127,362,000 after purchasing an additional 5,975 shares during the last quarter. Assenagon Asset Management S.A. increased its position in shares of Disc Medicine by 191.4% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,119,458 shares of the company's stock valued at $73,280,000 after purchasing an additional 735,300 shares during the last quarter. Opaleye Management Inc. increased its position in shares of Disc Medicine by 103.1% during the 2nd quarter. Opaleye Management Inc. now owns 855,000 shares of the company's stock valued at $62,535,000 after purchasing an additional 434,000 shares during the last quarter. Finally, Jennison Associates LLC raised its holdings in Disc Medicine by 14.7% during the 1st quarter. Jennison Associates LLC now owns 610,382 shares of the company's stock valued at $39,028,000 after buying an additional 78,303 shares during the period. 83.70% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, COO Jonathan Yu sold 8,796 shares of Disc Medicine stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $83.12, for a total value of $731,123.52. Following the completion of the transaction, the chief operating officer owned 54,324 shares in the company, valued at approximately $4,515,410.88. This trade represents a 13.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO John D. Quisel sold 33,000 shares of Disc Medicine stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $79.15, for a total value of $2,611,950.00. Following the completion of the transaction, the chief executive officer owned 226,064 shares of the company's stock, valued at approximately $17,892,965.60. This represents a 12.74% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 168,046 shares of company stock worth $13,191,034. 3.76% of the stock is currently owned by corporate insiders.

Disc Medicine Company Profile

Disc Medicine, Inc NASDAQ: IRON is a clinical-stage biopharmaceutical company focused on developing treatments for serious hematologic diseases. Its research is centered on the biology of red blood cell production and iron homeostasis, with the goal of addressing disorders in which abnormal iron regulation or ineffective erythropoiesis contributes to disease.

The company's pipeline includes bitopertin, an investigational oral therapy designed to enhance red blood cell production through inhibition of glycine transporter 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.